AtriCure, Inc. (ATRC) Earnings Call Analysis

NASDAQ · Healthcare · Medical Instruments & Supplies

20/25

Growth 4 Margin 4 Expansion 5 Platform 3 Financial 4

latest quarter score

Earnings Reports

20
AtriCure (ATRC) Q2 2026: Pain Management Franchise Delivers 28% U.S. Growth, Extending Platform Lead
July 24, 2026
19
AtriCure (ATRC) Q1 2026: Gross Margin Expands 246 bps on U.S. Product Mix Surge
May 06, 2026
23
AtriCure (ATRC) Q4 2025: Open Appendage Management Jumps 24%, Offsetting Hybrid Decline
February 24, 2026
21
AtriCure (ATRC) Q3 2025: 16% Revenue Growth Accelerates Market Penetration and Profitability
October 29, 2025
23
AtriCure (ATRC) Q2 2025: Pain Management Franchise Surges 43%, Accelerating Non-Opioid Adoption
July 29, 2025
22
AtriCure (ATRC) Q1 2025: Flex Mini Drives 23% U.S. Open Growth, Extending Franchise Tailwinds
July 06, 2025
AtriCure (ATRC) Q3 2024: Pain Management Franchise Grows 36%, Fueling Cash Generation and Portfolio Expansion
October 29, 2024
Atricure (ATRC) Q2 2024: International Revenue Jumps 29%, Offsetting U.S. Hybrid Headwinds
July 30, 2024
AtriCure (ATRC) Q1 2024: Open Ablation Sales Up 16.5% as Innovation Offsets Competitive Pressure
May 01, 2024
16
AtriCure (ATRC) Q3 2023: Open Ablation Drives 20% Franchise Growth as R&D Outpaces SG&A
November 01, 2023
AtriCure (ATRC) Q2 2023: Encompass Clamp Penetration Tops 30%, Driving 23% Open Ablation Growth
July 25, 2023
AtriCure (ATRC) Q1 2023: Open Ablation Sales Surge 32%, Expanding U.S. Cardiac Penetration
May 02, 2023
AtriCure (ATRC) Q4 2022: Encompass Clamp Drives 20% Open Ablation Revenue Surge, Offsetting MIS Softness
February 21, 2023

Browse all companies